Key result
Rivaroxaban and other direct oral anticoagulants demonstrate favorable efficacy and safety for cancer-associated thrombosis, offering a viable alternative to low molecular weight heparins for patients with poor compliance to injectable therapies.
Why the study?
Does rivaroxaban improve efficacy and safety in patients with cancer-associated thrombosis compared to LMWH?
Does rivaroxaban improve efficacy and safety in patients with cancer-associated thrombosis compared to LMWH?
Rivaroxaban is emerging as a viable and often preferred alternative to LMWH for cancer-associated thrombosis, driven by poor compliance with injectable agents and comparable efficacy profiles.
May support DOAC use for cancer thrombosis with LMWH nonadherence; leaves open confirmatory randomized trials.
Patients with cancer have a high risk of developing cancer-associated thrombosis (CAT). Current guidelines suggest preferential use of low molecular weight heparins (LMWH) in CAT. The real-world data show that compliance with recommended LMWH therapy in cancer patients is low. Many patients discontinue injectable anticoagulants prematurely, in some cases even after a month, despite a high recurrence rate in this population. In recent years an increasing number of cancer patients are treated with direct oral anticoagulants, mainly rivaroxaban. Recent data confirming the safety and efficacy of rivaroxaban are starting to emerge and support the growing trend of using direct oral anticoagulants in cancer patients. If positive results of the recently completed SELECT-D trial are confirmed in the upcoming trials and registries of CALLISTO project, the guidelines for the treatment of CAT will have to be revised in favour of DOAC use in cancer-associated thrombosis.
No takes yet. Share an insight, caveat, or question.
Halena et al. (2018) conducted a review in Cancer-associated thrombosis. Rivaroxaban vs. Low molecular weight heparins (LMWH) was evaluated. Rivaroxaban and other direct oral anticoagulants demonstrate favorable efficacy and safety for cancer-associated thrombosis, offering a viable alternative to low molecular weight heparins for patients with poor compliance to injectable therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: